Janssen investigational COVID-19 vaccine: Interim analysis of phase 3 clinical data released
Study reveals wide health disparity between different ethinc groups in England
29 January 2021Cervical cancer screening rates dropped during stay-at-home order
29 January 2021Janssen investigational COVID-19 vaccine: Interim analysis of phase 3 clinical data released
An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.
